Valbenazine and Deutetrabenazine for Tardive Dyskinesia

Innovations in Clinical Neuroscience

Jonathan R. Scarff¹  Katie T. B. Touma² 

[1] Dr. Scarff is with the Department of Behavioral Health at Kenner Army Health Clinic in Fort Lee, Virginia.;Dr. Touma is with the William Jennings Bryan Dorn VA Medical Center Community-based Outpatient Clinic in Anderson, South Carolina.

关键词: Valbenazine;    deutetrabenazine;    tardive dyskinesia;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Tardive dyskinesia (TD) is a medication-induced permanent movement disorder with no United States Food and Drug Administration (FDA)-approved treatments prior to 2017. Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treatment of TD. They offer a unique mechanism of action by inhibiting vesicular monoamine transporter type 2. The objective of this review is to discuss the efficacy, tolerability, dosing, drug interactions, and precautions for valbenazine and deutetrabenazine.

【 授权许可】

Unknown